Literature DB >> 10991943

Domain interactions in the gelatinase A.TIMP-2.MT1-MMP activation complex. The ectodomain of the 44-kDa form of membrane type-1 matrix metalloproteinase does not modulate gelatinase A activation.

C M Overall1, E Tam, G A McQuibban, C Morrison, U M Wallon, H F Bigg, A E King, C R Roberts.   

Abstract

On the cell surface, the 59-kDa membrane type 1-matrix metalloproteinase (MT1-MMP) activates the 72-kDa progelatinase A (MMP-2) after binding the tissue inhibitor of metalloproteinases (TIMP)-2. A 44-kDa remnant of MT1-MMP, with an N terminus at Gly(285), is also present on the cell after autolytic shedding of the catalytic domain from the hemopexin carboxyl (C) domain, but its role in gelatinase A activation is unknown. We investigated intermolecular interactions in the gelatinase A activation complex using recombinant proteins, domains, and peptides, yeast two-hybrid analysis, solid- and solution-phase assays, cell culture, and immunocytochemistry. A strong interaction between the TIMP-2 C domain (Glu(153)-Pro(221)) and the gelatinase A hemopexin C domain (Gly(446)-Cys(660)) was demonstrated by the yeast two-hybrid system. Epitope masking studies showed that the anionic TIMP-2 C tail lost immunoreactivity after binding, indicating that the tail was buried in the complex. Using recombinant MT1-MMP hemopexin C domain (Gly(285)-Cys(508)), no direct role for the 44-kDa form of MT1-MMP in cell surface activation of progelatinase A was found. Exogenous hemopexin C domain of gelatinase A, but not that of MT1-MMP, blocked the cleavage of the 68-kDa gelatinase A activation intermediate to the fully active 66-kDa enzyme by concanavalin A-stimulated cells. The MT1-MMP hemopexin C domain did not form homodimers nor did it bind the gelatinase A hemopexin C domain, the C tail of TIMP-2, or full-length TIMP-2. Hence, the ectodomain of the remnant 44-kDa form of MT1-MMP appears to play little if any role in the activation of gelatinase A favoring the hypothesis that it accumulates on the cell surface as an inactive, stable degradation product.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10991943     DOI: 10.1074/jbc.M005932200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

Review 1.  Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases.

Authors:  Klaus Maskos; Wolfram Bode
Journal:  Mol Biotechnol       Date:  2003-11       Impact factor: 2.695

2.  Peptide from the C-terminal domain of tissue inhibitor of matrix metalloproteinases-2 (TIMP-2) inhibits membrane activation of matrix metalloproteinase-2 (MMP-2).

Authors:  Xiaoping Xu; Margarita Mikhailova; Zhihua Chen; Sanjay Pal; Trista K Robichaud; Eileen M Lafer; Sam Baber; Bjorn Steffensen
Journal:  Matrix Biol       Date:  2011-08-04       Impact factor: 11.583

Review 3.  Membrane-type matrix metalloproteinases (MT-MMPs): expression and function during glioma invasion.

Authors:  H L Fillmore; T E VanMeter; W C Broaddus
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

4.  Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2.

Authors:  Ekaterina Morgunova; Ari Tuuttila; Ulrich Bergmann; Karl Tryggvason
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

5.  Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression.

Authors:  Meena B Bansal; Kellen Kovalovich; Ritu Gupta; Wei Li; Akansha Agarwal; Brian Radbill; Carlos E Alvarez; Rifaat Safadi; M Isabel Fiel; Scott L Friedman; Rebecca A Taub
Journal:  J Hepatol       Date:  2005-04       Impact factor: 25.083

6.  Matrix metalloproteinases promote inflammation and fibrosis in asbestos-induced lung injury in mice.

Authors:  Roderick J Tan; Cheryl L Fattman; Laura M Niehouse; Jacob M Tobolewski; Lana E Hanford; Qinglang Li; Federico A Monzon; William C Parks; Tim D Oury
Journal:  Am J Respir Cell Mol Biol       Date:  2006-03-30       Impact factor: 6.914

Review 7.  MMPs and ADAMs/ADAMTS inhibition therapy of abdominal aortic aneurysm.

Authors:  Yongqi Li; Weicheng Wang; Lei Li; Raouf A Khalil
Journal:  Life Sci       Date:  2020-04-10       Impact factor: 5.037

8.  The CXCR4/SDF1 axis improves muscle regeneration through MMP-10 activity.

Authors:  Miriam Bobadilla; Neira Sainz; Gloria Abizanda; Josune Orbe; José Antonio Rodriguez; José Antonio Páramo; Felipe Prósper; Ana Pérez-Ruiz
Journal:  Stem Cells Dev       Date:  2014-03-14       Impact factor: 3.272

9.  Induction of membrane-type-1 matrix metalloproteinase by epidermal growth factor-mediated signaling in gliomas.

Authors:  Timothy E Van Meter; William C Broaddus; Harcharan K Rooprai; Geoffrey J Pilkington; Helen L Fillmore
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

Review 10.  Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites.

Authors:  Christopher M Overall
Journal:  Mol Biotechnol       Date:  2002-09       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.